Alzheimer’s Therapy Case Study
Alzheimer disorder is a continuous neurodegenerative disorder with a high statistical growth in the modern world. Research shows that the number of individuals with Alzheimer’s Disorder dementia is estimated to triple by the year 2050. The rise in Alzheimer’s Disorder prevalence has heightened the importance of more research on Alzheimer’s Disorder treatment. Past information and data have revealed that ancient medicine can be a source of motivation and inspiration to acquire new therapies (Maruish, 2012). There is a type of dementia in ancient Iranian medicine with similar signs and symptoms of Alzheimer’s Disorder. Iranian ancient medicine explains the causes of disorders by recognized Greek concept, the humorist. In this concept, all human organs have a health temperament that has four essential qualities such as coldness, hotness, wetness and dryness. When the equilibrium state of these qualities is disturbed, the organs transform to unhealthy temperament which was traditionally referred to as “intemperament.” For example, if the temperament of the brain is exposed to coldness, cold intemperament in the brain will happen. By this concept, ancient Iranian medicine categorizes dementia into four groups: cold and wet, simple cold, hot and dry and cold and dry. This paper focuses on how therapy can be provided in the case of a seventy-six old man diagnosed with Alzheimer’s disorder.
Decision Point One
Begin Aricept (donepezil) 5 mg orally at Bedtime
Reason for Selection
The individual was diagnosed with Alzheimer’s disorder which is treatable by donepezil. This drug is utilized to treat dementia related to Alzheimer’s disorder (Rothschild, 2014). Donepezil does not cure Alzheimer’s disorder, but it improves the awareness, ability to function and memory. This drug blocks enzymes and restores the balance of neurotransmitters in the brain. The dosage is based on the health response and condition for treatment. To lower side effects such as diarrhoea and nausea, a health care practitioner starts donepezil medication at a low dose and increases the dose with time.
Donepezil is a quality drug expected to yield therapeutic results after two to three weeks. By the end of the third week, the patient is expected to improve his/her awareness and regain proper memory (Yusuf, 2015). Moreover, the patient should have a lower score on the MMSE, which should drop by about 25% from the previous score.
Differences between Expected and Actual Results
The patient returns to the clinic after four weeks. He is still disinterested in attending church activities and proceeds to exhibit disinhibited actions. Moreover, MMSE was administered to the patient where the scores were 18 out of 30 (Siemers, 2014). There were improvements in the results, hence expectations that the therapy would work.